Vertex Pharmaceuticals VRTX Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's deferred tax assets and other non-current assets?
- Vertex Pharmaceuticals (VRTX) reported deferred tax assets and other non-current assets of $1.26B in Q1 2026.
- How has Vertex Pharmaceuticals's deferred tax assets and other non-current assets changed year-over-year?
- Vertex Pharmaceuticals's deferred tax assets and other non-current assets increased by 24.7% year-over-year, from $1.01B to $1.26B.
- What is the long-term trend for Vertex Pharmaceuticals's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's deferred tax assets and other non-current assets has grown at a 90.5% compound annual growth rate (CAGR), from $49.3M to $1.24B.